Chemocentryx Revenue Growth Rates (CCXI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Chemocentryx Inc.  (NASDAQ: CCXI)
 

CCXI's Revenue Growth by Quarter and Year

Chemocentryx's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CCXI/growth
https://api.csimarket.com/api/v1/companies/CCXI/fundamentals
https://api.csimarket.com/api/v1/companies/CCXI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CCXI Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00

CCXIs Annual Revenue
Chemocentryx's Revenue in the fiscal year 2021 $ 64.45 millions
Chemocentryx's Revenue in the fiscal year 2020 $ 0.00 millions
Chemocentryx's Revenue in the fiscal year 2019 $ 72.26 millions
Chemocentryx's Revenue in the fiscal year 2018 $ 85.75 millions
Chemocentryx's Revenue in the fiscal year 2017 $ 82.50 millions




CCXI Revenue third quarter 2022 Y/Y Growth Comment
Chemocentryx Inc. in the third quarter 2022 recorded of $ 0.00 millions.

According to the results reported in the third quarter 2022, Chemocentryx Inc. achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Chemocentryx Inc.' s Revenue meltdown of -100% ranks overall at the positon no. in the third quarter 2022.


CCXI Revenue ( Y/Y Growth %) 2022
 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Chemocentryx's third quarter 2022 Revenue $ 0.00 millions CCXI's Income Statement
Chemocentryx's third quarter 2021 Revenue $ 23.53 millions Quarterly CCXI's Income Statement


CCXI Revenue (Quarter on Quarter Growth %)

 2022
 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March -
FY (Year on Year)   -


Back to CCXI Growth rate Comparisons >> Back to CCXI Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Mar 31 2018)   (Dec 31 2012)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Mar 31 2018)   (Dec 31 2012)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Chemocentryx's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CCXI's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CCXI's III. Quarter Q/Q Revenue Comment


Chemocentryx's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending (Mar 31 2022) 12 Months Ending (Dec 31 2021) 12 Months Ending (Sep 30 2021) 12 Months Ending (Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 74.56
Y / Y Revenue Growth (TTM) 91.87 %
Year on Year Revenue Growth Overall Ranking # 4140
Seqeuential Revenue Change (TTM) 36.41 %
Seq. Revenue Growth (TTM) Overall Ranking # 4132


Cumulative Revenue growth Comment
Chemocentryx saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 91.87% year on year, to $ 75 millions if the fiscal year would have ended in Jun 30 2022.
Chemocentryx's trailing twelve months Revenue growth was higher than company's average 32.6% and higher than -59.24% growth in Mar 31 2022.
But from twelve months ended Mar 31 2022 rise was beneth at 36.41 % from $54.66 millions achieved in the period from Mar 31 2022 to Jun 30 2021.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 32.6%.

In the Healthcare sector 628 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 400 to 4140.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 242
Healthcare Sector # 629
Overall # 4140

Revenue TTM Y/Y Growth Statistics
High Average Low
315.64 %
 32.6 %
-82.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 242
Sector # 628
S&P 500 # 4132
Cumulative Revenue growth Comment
Chemocentryx saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 91.87% year on year, to $ 75 millions if the fiscal year would have ended in Jun 30 2022.
Chemocentryx's trailing twelve months Revenue growth was higher than company's average 32.6% and higher than -59.24% growth in Mar 31 2022.
But from twelve months ended Mar 31 2022 rise was beneth at 36.41 % from $54.66 millions achieved in the period from Mar 31 2022 to Jun 30 2021.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 32.6%.
The momentum is even more impressive from twelve months ended Mar 31 2022 exhibited at 36.41 % increase from $54.66 millions in the period from Mar 31 2022 to Jun 30 2021.

In the Healthcare sector 628 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 400 to 4140.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 242
Healthcare Sector # 629
Overall # 4140

Revenue TTM Y/Y Growth Statistics
High Average Low
315.64 %
32.6 %
-82.89 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CCXI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Chemocentryx Revenue Growth Rates (CCXI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Chemocentryx Inc (CIK 1340652).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-015596
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Chemocentryx Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.